Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
September 02 2021 - 7:00AM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers, today announced that Anthony Sun, MD, Chairman
and Chief Executive Officer of Zentalis, will participate in two
upcoming virtual investor conferences.
Presentation Details:
Event: Morgan Stanley Global Healthcare
ConferenceDate: Friday, September 10th,
2021Time: 2:45 p.m. EDTFormat:
Live Fireside Chat
Event: H.C. Wainwright Global Life Sciences
Conference Date: Monday, September 13th,
2021Time: 7:00 a.m. EDTFormat: On
Demand Corporate Presentation
Webcasts from the Morgan Stanley fireside chat and H.C.
Wainwright corporate presentation will be accessible through the
Investors section of the Company’s website at www.zentalis.com.
Following the events, archived webcasts will be available on the
Zentalis website.
About Zentalis
Zentalis Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers. The Company is developing a broad pipeline of
potentially best-in-class oncology candidates, all internally
discovered, which include ZN-c3, a WEE1 inhibitor for advanced
solid tumors, ZN-c5, an oral selective estrogen receptor degrader
(SERD) for ER+/HER2- breast cancer, ZN-d5, a BCL-2 inhibitor for
hematologic malignancies, and ZN-e4, an EGFR inhibitor for
non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c3,
ZN-c5 and ZN-d5 to its majority-owned joint venture, Zentera
Therapeutics, to develop and commercialize these candidates in
China. Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our participation in upcoming events and presentations.
These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to the important factors
discussed under the caption “Risk Factors” in our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2021 filed with the
U.S. Securities and Exchange Commission (SEC) and our other filings
with the SEC. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change.
Investor Contact:
Gitanjali Jain
Solebury Trout
gogawa@soleburytrout.com
Media Contact:
Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2023 to Apr 2024